Ask Lazlo

life sciences… only

King and Alpharma = $1.6B Deal

After months of courting (read, hostile negotiation) King Pharmaceuticals has finally reached a deal to acquire drugmaker Alpharma for $1.6B.  An earlier bid of $1.4B was rejected in August.

Alpharma made news earlier this month when it’s painkilling compound, Embeda, was shown to have less potential for addiction than stand-alone morphine.  

Analysts commented that the deal clearly made sense, though the currently unfavorable economic climate led to a less attractive loan package for King.


November 25, 2008 - Posted by | Deals, Pharma

No comments yet.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: